Should You Buy Kazia Therapeutics Ltd (KZIA) in Biotechnology Industry?

Friday, August 7, 2020 10:21 AM | InvestorsObserver Analysts

Kazia Therapeutics Ltd (KZIA) is near the middle in its industry group according to InvestorsObserver. KZIA gets an overall rating of 49. That means it scores higher than 49 percent of stocks. Kazia Therapeutics Ltd gets a 45 rank in the Biotechnology industry. Biotechnology is number 16 out of 148 industries.

Overall Score - 49
KZIA has an Overall Score of 49. Find out what this means to you and get the rest of the rankings on KZIA!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Kazia Therapeutics Ltd Stock Today?

Kazia Therapeutics Ltd (KZIA) stock is higher by 72.94% while the S&P 500 is unchanged 0% as of 10:03 AM on Friday, Aug 7. KZIA is higher by $3.10 from the previous closing price of $4.25 on volume of 9,836,798 shares. Over the past year the S&P 500 is higher by 13.99% while KZIA is higher by 196.37%. KZIA lost -$1.23 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Kazia Therapeutics Ltd click here.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Do Analysts Expect Inovio Pharmaceuticals Inc (INO) Stock to Rise?

Is Veeva Systems Inc (VEEV) The Right Choice in Health Information Services?

Is Evolus Inc (EOLS) a Winner in the Drug Manufacturers - Specialty & Generic Industry?

Is Pfenex Inc (PFNX) Stock Near the Top of the Biotechnology Industry?

How Will the Market React to Obseva SA (OBSV) Stock Getting a Bearish Rating

Should You Buy Moderna Inc (MRNA) Stock on Monday?

Related Companies